You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKesson
Johnson and Johnson
Dow
Mallinckrodt

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,394,826


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,394,826
Title:Dual mechanism inhibitors for the treatment of disease
Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
Inventor(s): deLong; Mitchell A. (Chapel Hill, NC), Sturdivant; Jill Marie (Chapel Hill, NC), Royalty; Susan M. (Cary, NC)
Assignee: Aerie Pharmaceuticals, Inc. (Research Triangle Park, NC)
Application Number:12/694,965
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,394,826

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aerie Pharms Inc RHOPRESSA netarsudil mesylate SOLUTION/DROPS;OPHTHALMIC 208254-001 Dec 18, 2017 RX Yes Yes   Start Trial   Start Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE   Start Trial
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes   Start Trial   Start Trial Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,394,826

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010241996   Start Trial
Australia 2010242800   Start Trial
Australia 2016201754   Start Trial
Australia 2017248440   Start Trial
Australia 2019210632   Start Trial
Canada 2760562   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Harvard Business School
Boehringer Ingelheim
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.